Gyre Therapeutics, Inc. (GYRE) vs Jade Biosciences, Inc. (JBIO)

A side-by-side comparison of Gyre Therapeutics, Inc. and Jade Biosciences, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — GYRE vs JBIO

growth of $100 · dividends reinvested · last 5y
GYRE -20.9% (-4.6%/yr)JBIO -97.8% (-53.5%/yr)GYRE compounded faster over this window
Log scale — wide-divergence pair
1101001kStart $10020222023202420252026$79$2
GYRE JBIO

GYRE vs JBIO: by the numbers

  • •JBIO is the larger company ($825M vs $802M market cap).
  • •Both run net losses; JBIO's is the smaller (0.00% vs -14.52% net margin).

Metrics side by side

Valuation

MetricGYREJBIO
P/S ratio6.72N/A
P/B ratio7.431.88

Profitability

MetricGYREJBIO
Gross margin94.30%0.00%
Operating margin9.86%0.00%
Net margin-14.52%0.00%
ROE-13.30%-34.83%
ROIC-9.77%-37.39%

Growth (annualized)

MetricGYREJBIO
Revenue CAGR (5Y)84.92%N/A
Total return CAGR (5Y)-0.34%-52.65%

Frequently asked

How have GYRE and JBIO total returns compared?
Over the past 5 years, GYRE delivered -0.34% and JBIO delivered -52.65% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.